Dianthus Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.0M | $6.2M | $2.8M | — | — | — | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $145.6M | $83.1M | $32.8M | $29.4M | $46.8M | $50.6M | $59.2M |
| SG&A Expense | — | $34.3M | $25.0M | $18.2M | $6.7M | $27.9M | $28.1M | $23.8M |
| Operating Income | — | $-177.9M | $-101.9M | $-48.2M | $-29.7M | $-74.7M | $-78.7M | $-83.0M |
| Operating Margin | — | -8,739.3% | -1,633.7% | -1,704.7% | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-162.3M | $-85.0M | $-43.6M | $-28.5M | $-71.1M | $-74.9M | $-76.8M |
| Net Margin | — | -7,973.3% | -1,362.8% | -1,541.2% | — | — | — | — |
| EPS (Basic) | — | $-4.20 | $-2.55 | $-1.41 | $-0.90 | $-0.04 | $-0.05 | $-0.06 |
| EPS (Diluted) | — | $-4.20 | $-2.55 | $-1.41 | $-0.90 | $-0.04 | $-0.05 | $-0.06 |
| Shares Outstanding (Basic) | 44.5M | 38.6M | 33.3M | 30.9M | 31.5M | 1.98B | 1.58B | 1.41B |
| Shares Outstanding (Diluted) | 44.5M | 38.6M | 33.3M | 30.9M | 31.5M | 1.98B | 1.58B | 1.41B |
| Dividends Per Share | — | $0.00 | $0.00 | $0.00 | — | — | — | — |